Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; 3rd Department of Internal Medicine, 1(st) Faculty of Medicine, Charles University, Prague, Czech Republic.
Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic.
Gene. 2023 Jan 15;849:146921. doi: 10.1016/j.gene.2022.146921. Epub 2022 Sep 26.
Type 2 diabetes mellitus (T2DM) is a prototypical complex disease with polygenic architecture playing an important role in determining susceptibility to develop the disease (and its complications) in subjects exposed to modifiable lifestyle factors. A current challenge is to quantify the degree of the individual's genetic risk using genetic risk scores (GRS) capturing the results of genome-wide association studies while incorporating possible ethnicity- or population-specific differences.
This study included three groups of T2DM (T2DM-I, N = 1,032; T2DM-II, N = 353; and T2DM-III, N = 399) patients and 2,481 diabetes-free subjects. The status of the microvascular and macrovascular diabetes complications were known for the T2DM-I patients. Overall, 21 single nucleotide polymorphisms (SNPs) were analyzed, and selected subsets were used to determine the GRS (both weighted - wGRS and unweighted - uGRS) for T2DM risk predictions (6 SNPs) and for predicting the risks of complications (7 SNPs).
The strongest T2DM markers (P < 0.0001) were within the genes for TCF7L2 (transcription factor 7-like 2), FTO (fat mass and obesity associated protein) and ARAP1 (ankyrin repeat and PH domain 1). The T2DM-I subjects with uGRS values greater (Odds Ratio, 95 % Confidence Interval) than six had at least twice (2.00, 1.72-2.32) the risk of T2DM development (P < 0.0001), and these results were confirmed in the independent groups (T2DM-II 1.82, 1.45-2.27; T2DM-III 2.63, 2.11-3.27). The wGRS (>0.6) further improved (P < 0.000001) the risk estimations for all three T2DM groups. The uGRS was also a significant predictor of neuropathy (P < 0.0001), nephropathy (P < 0.005) and leg ischemia (P < 0.0005).
If carefully selected and specified, GRS, both weighted and unweighted, could be significant predictors of T2DM development, as well as the diabetes complications development.
2 型糖尿病(T2DM)是一种典型的复杂疾病,其多基因结构在决定易患因素方面起着重要作用,这些易患因素使个体暴露于可改变的生活方式因素后易发展为该疾病(及其并发症)。目前面临的挑战是使用遗传风险评分(GRS)量化个体的遗传风险程度,该评分可捕获全基因组关联研究的结果,同时纳入可能存在的种族或人群特异性差异。
本研究纳入了三组 T2DM(T2DM-I,N=1032;T2DM-II,N=353;T2DM-III,N=399)患者和 2481 名无糖尿病患者。T2DM-I 患者的微血管和大血管糖尿病并发症状态已知。总体上,分析了 21 个单核苷酸多态性(SNP),并选择了一些亚组来确定 T2DM 风险预测的 GRS(加权 - wGRS 和未加权 - uGRS)(6 个 SNP)和预测并发症风险的 GRS(7 个 SNP)。
最强的 T2DM 标志物(P<0.0001)位于 TCF7L2(转录因子 7 样 2)、FTO(脂肪量和肥胖相关蛋白)和 ARAP1(锚蛋白重复和 PH 结构域 1)基因内。uGRS 值大于(优势比,95%置信区间)六个的 T2DM-I 患者发生 T2DM 发展的风险至少增加两倍(2.00,1.72-2.32)(P<0.0001),并且这些结果在独立组中得到了证实(T2DM-II 1.82,1.45-2.27;T2DM-III 2.63,2.11-3.27)。wGRS(>0.6)进一步提高了所有三组 T2DM 患者的风险估计值(P<0.000001)。uGRS 也是神经病变(P<0.0001)、肾病(P<0.005)和腿部缺血(P<0.0005)的显著预测因子。
如果精心选择和指定,加权和未加权的 GRS 都可以成为 T2DM 发展以及糖尿病并发症发展的重要预测因子。